RESUMEN
OBJECTIVES: Phenobarbital serves as an antiepileptic drug (AED) and finds application in the treatment of epilepsy either as monotherapy or adjunctive therapy. This drug exhibits various pharmacodynamic properties that account for its beneficial effects as well as potential side effects. Accurate measurement of its concentration is critical for optimizing AED therapy through appropriate dose adjustments. Therefore, our objective was to develop and validate a new reference measurement procedure (RMP) for the accurate quantification of phenobarbital levels in human serum and plasma. METHODS: A sample preparation protocol based on protein precipitation followed by a high dilution step was established in combination with a liquid chromatography-tandem mass spectrometry (LC-MS/MS) method using a C8 column to separate target analytes from known and unknown interferences. Assay validation and determination of measurement uncertainty were performed based on current guidelines. Selectivity and Specificity were assessed using spiked serum and plasma samples; to investigate possible matrix effects (MEs) a post-column infusion experiment and a comparison of standard line slopes was performed. Precision and accuracy were determined within a multiday precision experiment. RESULTS: The RMP was shown to be highly selective and specific, with no evidence of matrix interferences. It can be used to quantify phenobarbital in the range of 1.92 to 72.0⯵g/mL. Intermediate precision was less than 3.2â¯%, and repeatability coefficient of variation (CV) ranged from 1.3 to 2.0â¯% across all concentration levels. The relative mean bias ranged from -3.0 to -0.7â¯% for native serum levels, and from -2.8 to 0.8â¯% for Li-heparin plasma levels. The measurement uncertainties (k=1) for single measurements and target value assignment were 1.9 to 3.3â¯% and 0.9 to 1.6â¯%, respectively. CONCLUSIONS: A novel LC-MS/MS-based candidate RMP for the quantification of phenobarbital in human serum and plasma is presented which can be used for the standardization of routine assays and the evaluation of clinically relevant samples.
Asunto(s)
Fenobarbital , Espectrometría de Masas en Tándem , Humanos , Fenobarbital/sangre , Espectrometría de Masas en Tándem/métodos , Espectrometría de Masas en Tándem/normas , Cromatografía Liquida/métodos , Cromatografía Liquida/normas , Anticonvulsivantes/sangre , Estándares de Referencia , Análisis Químico de la Sangre/métodos , Análisis Químico de la Sangre/normas , Técnicas de Dilución del Indicador , Cromatografía Líquida con Espectrometría de MasasRESUMEN
OBJECTIVES: A reference measurement procedure (RMP) using isotope dilution liquid chromatography-tandem mass spectrometry (ID-LC-MS/MS) was developed and validated with the aim of accurately measuring carbamazepine-10,11-epoxide concentrations in human serum and plasma. METHODS: To establish traceability to SI units, the absolute content of the reference material was determined using quantitative nuclear magnetic resonance (qNMR) spectroscopy. As sample preparation a protein precipitation protocol followed by a high dilution step was established. Chromatographic separation from carbamazepine and potential metabolites was achieved using a C18 stationary phase. Selectivity, specificity, matrix effects, precision and accuracy, inter-laboratory equivalence, and uncertainty of measurement were evaluated based on guidelines from the Clinical and Laboratory Standards Institute, the International Conference on Harmonization, and the Guide to the Expression of Uncertainty in Measurement. RESULTS: The RMP demonstrated very good selectivity and specificity, showing no evidence of a matrix effect. This enabled accurate quantification of carbamazepine-epoxide in the concentration range of 0.0400-12.0⯵g/mL. The intermediate precision was found to be less than 2.1â¯%, and the repeatability coefficient of variation (CV) ranged from 1.2 to 1.8â¯% across all concentration levels. Regarding accuracy, the relative mean bias varied from 1.4 to 2.5â¯% for native serum levels and from 1.4 to 3.5â¯% for Li-heparin plasma levels. The measurement uncertainty for single measurements ranged from 1.6 to 2.1â¯%. CONCLUSIONS: In this study, we introduce a new LC-MS/MS-based candidate RMP for accurately measuring carbamazepine-10,11-epoxide in human serum and plasma. This novel method offers a traceable and dependable platform, making it suitable for standardizing routine assays and assessing clinically relevant samples.
Asunto(s)
Carbamazepina , Espectrometría de Masas en Tándem , Humanos , Espectrometría de Masas en Tándem/métodos , Espectrometría de Masas en Tándem/normas , Carbamazepina/sangre , Carbamazepina/análogos & derivados , Cromatografía Liquida/métodos , Cromatografía Liquida/normas , Estándares de Referencia , Técnicas de Dilución del Indicador , Cromatografía Líquida con Espectrometría de MasasRESUMEN
OBJECTIVES: Primidone is an anticonvulsive drug used in the treatment of epilepsy and essential tremor. It offers beneficial effects in controlling seizures, but its usage is also associated with possible side effects. To ensure optimal therapy, it is crucial to measure its concentration through accurate quantification methods. Therefore, our main goal was to develop and validate a new reference measurement procedure (RMP) for accurately measuring primidone levels in human serum and plasma. METHODS: In our study, we focused on the separation of primidone from both known and unknown interferences using a C18 column. To achieve accurate sample preparation, we developed a protocol involving protein precipitation followed by a high dilution step. The validation of the assay and determination of measurement uncertainty were carried out following guidelines from organizations such as the Clinical and Laboratory Standards Institute, the International Conference on Harmonization, and the Guide to the Expression of Uncertainty in Measurement. These rigorous validation processes ensure the reliability and accuracy of our method for quantifying primidone levels in human serum and plasma samples. RESULTS: The RMP was shown to be highly selective and specific, with no evidence of matrix interference. It can be used to quantify primidone in the range of 0.150-30.0⯵g/mL. Intermediate precision was less than 4.0â¯%, and repeatability CV ranged from 1.0 to 3.3â¯% across all concentration levels. The relative mean bias ranged from 0.1 to 3.9â¯% for native serum levels, and from -2.6 to 2.8â¯% for lithium-heparin plasma levels. The measurement uncertainties for single measurements and target value assignment were 1.5-4.1â¯% and 0.9-1.0â¯%, respectively. CONCLUSIONS: In this study, we introduce an innovative LC-MS/MS-based candidate RMP specifically designed for primidone in human serum and plasma. Our RMP offers a traceable platform, facilitating the standardization of routine assays and enabling the evaluation of clinically relevant samples. With this novel approach, we aim to enhance the accuracy and reliability of primidone measurements, ultimately benefiting the field of clinical research and patient care.
Asunto(s)
Primidona , Espectrometría de Masas en Tándem , Humanos , Espectrometría de Masas en Tándem/métodos , Espectrometría de Masas en Tándem/normas , Primidona/sangre , Cromatografía Liquida/métodos , Cromatografía Liquida/normas , Estándares de Referencia , Reproducibilidad de los Resultados , Técnicas de Dilución del Indicador , Límite de Detección , Anticonvulsivantes/sangre , Cromatografía Líquida con Espectrometría de MasasRESUMEN
OBJECTIVES: To describe and validate an isotope dilution-liquid chromatograph-tandem mass spectrometry (ID-LC-MS/MS) based reference measurement procedure (RMP) for zonisamide to accurately measure serum and plasma concentrations. METHODS: Quantitative nuclear magnetic resonance (qNMR) spectroscopy was employed to determine the absolute content of the reference material used in order to establish traceability to SI units. Separation of zonisamide from known or unknown interferences was performed on a C8 column. For sample preparation a protocol based on protein precipitation in combination with a high dilution step was established. Assay validation and determination of measurement uncertainty were performed based on guidelines from the Clinical and Laboratory Standards Institute, the International Conference on Harmonization, and the Guide to the expression of uncertainty in measurement. RESULTS: The RMP was proven to be highly selective and specific with no evidence of a matrix effect, allowing for quantification of zonisamide within the range of 1.50-60.0⯵g/mL. Intermediate precision was <1.4â¯% and repeatability CV ranged from 0.7 to 1.2â¯% over all concentration levels. The relative mean bias ranged from 0.0 to 0.8â¯% for native serum levels and from 0.2 to 2.0â¯% for Li-heparin plasma levels. The measurement uncertainties for single measurements and target value assignment ranged from 1.1 to 1.4â¯% and 0.8-1.0â¯%, respectively. CONCLUSIONS: We present a novel LC-MS/MS-based candidate RMP for zonisamide in human serum and plasma which provides a traceable and reliable platform for the standardization of routine assays and evaluation of clinically relevant samples.
Asunto(s)
Isoxazoles , Espectrometría de Masas en Tándem , Zonisamida , Humanos , Espectrometría de Masas en Tándem/métodos , Espectrometría de Masas en Tándem/normas , Zonisamida/sangre , Cromatografía Liquida/métodos , Cromatografía Liquida/normas , Isoxazoles/sangre , Estándares de Referencia , Técnicas de Dilución del Indicador , Análisis Químico de la Sangre/métodos , Análisis Químico de la Sangre/normas , Cromatografía Líquida con Espectrometría de MasasRESUMEN
OBJECTIVES: To describe and validate a reference measurement procedure (RMP) for gabapentin, employing quantitative nuclear magnetic resonance (qNMR) spectroscopy to determine the absolute content of the standard materials in combination with isotope dilution-liquid chromatograph-tandem mass spectrometry (ID-LC-MS/MS) to accurately measure serum and plasma concentrations. METHODS: A sample preparation protocol based on protein precipitation in combination with LC-MS/MS analysis using a C8 column for chromatographic separation was established for the quantification of gabapentin. Assay validation and determination of measurement uncertainty were performed according to guidance from the Clinical and Laboratory Standards Institute, the International Conference on Harmonization, and the Guide to the expression of uncertainty in measurement. ID-LC-MS/MS parameters evaluated included selectivity, specificity, matrix effects, precision and accuracy, inter-laboratory equivalence, and uncertainty of measurement. RESULTS: The use of qNMR provided traceability to International System (SI) units. The chromatographic assay was highly selective, allowing baseline separation of gabapentin and the gabapentin-lactam impurity, without observable matrix effects. Variability between injections, preparations, calibrations, and days (intermediate precision) was <2.3%, independent of the matrix, while the coefficient of variation for repeatability was 0.9-2.0% across all concentration levels. The relative mean bias ranged from -0.8-1.0% for serum and plasma samples. Passing-Bablok regression analysis indicated very good inter-laboratory agreement; the slope was 1.00 (95% confidence interval [CI] 0.98 to 1.03) and the intercept was -0.05 (95% CI -0.14 to 0.03). Pearson's correlation coefficient was ≥0.996. Expanded measurement uncertainties for single measurements were found to be ≤5.0% (k=2). CONCLUSIONS: This analytical protocol for gabapentin, utilizing traceable and selective qNMR and ID-LC-MS/MS techniques, allows for the standardization of routine tests and the reliable evaluation of clinical samples.
Asunto(s)
Plasma , Espectrometría de Masas en Tándem , Humanos , Cromatografía Liquida/métodos , Gabapentina , Espectrometría de Masas en Tándem/métodos , Técnicas de Dilución del Indicador , Isótopos , Estándares de ReferenciaRESUMEN
OBJECTIVES: We developed an isotope dilution (ID)-liquid chromatography-tandem mass spectrometry (LC-MS/MS)-based candidate reference measurement procedure (RMP) for lamotrigine in human serum and plasma, using quantitative nuclear magnetic resonance-characterized reference standards to ensure traceability to the International System of Units. METHODS: A sample preparation protocol based on protein precipitation combined with LC-MS/MS analysis using a C18 column for chromatographic separation was established for the quantification of lamotrigine in human serum and plasma. Assay validation was performed according to current guidelines. Spiked serum and plasma samples were used to assess selectivity and specificity; a post-column infusion experiment and comparison of standard line slopes were performed to ascertain possible matrix effects. Precision and accuracy were determined in a 5 days validation experiment. Measurement uncertainty was determined per the Guide to the Expression of Uncertainty in Measurement. RESULTS: The method allowed the quantification of lamotrigine in serum and plasma in a range of 0.600-24.0 µg/mL without any observable matrix effects. The relative mean bias (n=6) ranged from 1.7 to 3.7%; intermediate precision, including variances in between-day, -calibration, and -injection, was ≤2.4%, independent of the level and matrix. Total measurement uncertainty for a single measurement was ≤2.6%; expanded uncertainty was ≤5.2% (coverage factor k=2). CONCLUSIONS: This candidate RMP based on ID-LC-MS/MS provides a traceable and reliable platform for the standardization of routine assays and the evaluation of clinical samples.
Asunto(s)
Anticonvulsivantes , Espectrometría de Masas en Tándem , Humanos , Cromatografía Liquida/métodos , Lamotrigina , Espectrometría de Masas en Tándem/métodos , Isótopos , Estándares de ReferenciaRESUMEN
OBJECTIVES: An isotope dilution-liquid chromatography-tandem mass spectrometry (ID-LC MS/MS)-based candidate reference measurement procedure (RMP) for aldosterone quantification in human serum and plasma is presented. METHODS: The material used in this RMP was characterized by quantitative nuclear magnetic resonance (qNMR) to assure traceability to SI Units. For liquid chromatography-tandem mass spectrometry (LC-MS/MS) analysis a two-dimensional heart cut LC approach, in combination with an optimal supported liquid extraction protocol, was established for the accurate analysis of aldosterone in human serum and plasma in order to minimize matrix effects and avoid the co-elution of interferences. Assay validation was performed according to current guidelines. Selectivity and specificity were assessed using spiked serum; potential matrix effects were examined by a post column infusion experiment and the comparison of standard line slopes. An extensive protocol over 5 days was applied to determine precision, accuracy and trueness. Measurement uncertainty was evaluated according to the Guide to the Expression of Uncertainty in Measurement (GUM), for which three individual sample preparations were performed on at least two different days. RESULTS: The RMP allowed aldosterone quantification within the range of 20-1,200 pg/mL without interference from structurally-related compounds and no evidence of matrix effects. Intermediate precision was ≤4.7% and repeatability was 2.8-3.7% for all analyte concentrations. The bias ranged between -2.2 and 0.5% for all levels and matrices. Total measurement uncertainties for target value assignment (n=6) were found to be ≤2.3%; expanded uncertainties were ≤4.6% (k=2) for all levels. CONCLUSIONS: The RMP showed high analytical performance for aldosterone quantification in human serum and plasma. The traceability to SI units was established by qNMR content determination of aldosterone, which was utilized for direct calibration of the RMP. Thus, this candidate RMP is suitable for routine assay standardization and evaluation of clinical samples.
Asunto(s)
Aldosterona , Espectrometría de Masas en Tándem , Humanos , Cromatografía Liquida/métodos , Espectrometría de Masas en Tándem/métodos , Isótopos , Técnicas de Dilución del Indicador , Estándares de ReferenciaRESUMEN
OBJECTIVES: Topiramate is an antiepileptic drug (AED) used for the monotherapy or adjunctive treatment of epilepsy and for the prophylaxis of migraine. It has several pharmacodynamic properties that contribute to both its clinically useful properties and observed adverse effects. Accurate measurement of its concentration is therefore essential for dose adjustment/optimisation of AED therapy. Our aim was to develop and validate a novel reference measurement procedure (RMP) for the quantification of topiramate in human serum and plasma. METHODS: An isotope dilution-liquid chromatography-tandem mass spectrometry (ID-LC-MS/MS) method in combination with a protein-precipitation-based sample preparation allows for quantification of topiramate in human serum and plasma. To assure traceability to SI units, quantitative nuclear magnetic resonance (qNMR) was applied to characterize the reference material used as primary calibrator for this RMP. Matrix effects were determined by performing a post-column infusion experiment and comparing standard line slopes. Accuracy and precision was evaluated performing an extensive five day precision experiment and measurement uncertainty was evaluated according Guide to the Expression of Uncertainty in Measurement (GUM). RESULTS: The method enabled topiramate quantification within the range of 1.20-36.0⯵g/mL without interference from structurally related compounds and no evidence of a matrix effect. Intermediate precision was ≤3.2â¯% and repeatability was 1.4-2.5â¯% across all concentration levels. The relative mean bias was -0.3 to 3.5â¯%. Expanded measurement uncertainties for target value assignment (n=6) were found to be ≤2.9â¯% (k=2) independent of the concentration level and the nature of the sample. CONCLUSIONS: In human serum and plasma, the RMP demonstrated high analytical performance for topiramate quantification and fulfilled the requirements on measurement uncertainty. Traceability to SI units was established by qNMR content determination of the topiramate, which was used for direct calibration of the RMP. This RMP is, therefore, fit for purpose for routine assay standardization and clinical sample evaluation.
Asunto(s)
Plasma , Espectrometría de Masas en Tándem , Humanos , Cromatografía Liquida/métodos , Topiramato , Espectrometría de Masas en Tándem/métodos , Técnicas de Dilución del Indicador , Anticonvulsivantes , Isótopos , Estándares de ReferenciaRESUMEN
OBJECTIVES: An isotope dilution liquid chromatography-tandem mass spectrometry (ID-LC-MS/MS)-based candidate reference measurement procedure (RMP) was developed and validated to accurately measure serum and plasma concentrations of carbamazepine. METHODS: Quantitative nuclear magnetic resonance (qNMR) spectroscopy was used to determine the absolute content of the reference material, ensuring its traceability to SI units. The separation of carbamazepine from potential interferences, whether known or unknown, was achieved using a C18 column. A protein precipitation protocol followed by a high dilution step was established for sample preparation. Assay validation and determination of measurement uncertainty were performed in accordance with the guidelines of the Clinical and Laboratory Standards Institute, the International Conference on Harmonization (ICH), and the Guide to the Expression of Uncertainty in Measurement (GUM). In order to demonstrate equivalence to the already existing RMP a method comparison study was performed. RESULTS: The RMP was proven to be highly selective and specific with no evidence of a matrix effect, allowing for quantification of carbamazepine within the range of 0.800-18.0⯵g/mL. Intermediate precision and repeatability (n=60 measurements) was found to be <1.6â¯% and <1.3â¯% over all concentration levels and independent from the matrix. The relative mean bias ranged from -0.1 to 0.6â¯% for native serum and from -0.3 to -0.1â¯% for Li-heparin plasma levels. The measurement uncertainties for single measurements and target value assignment were found to be <1.8â¯% and <1.3â¯%, respectively. Method comparison showed a good agreement between the Joint Committee of Traceability in Laboratory Medicine (JCTLM) listed RMP and the candidate RMP resulting in a Passing-Bablok regression equation with a slope of 1.01 and an intercept of -0.01. The bias in the patient cohort was found to be 0.9â¯%. CONCLUSIONS: We present a novel LC-MS/MS-based candidate RMP for carbamazepine in human serum and plasma which provides a traceable and reliable platform for the standardization of routine assays and evaluation of clinically relevant samples.
RESUMEN
OBJECTIVES: To develop an isotope dilution-liquid chromatography-tandem mass spectrometry (LC-MS/MS)-based candidate reference measurement procedure (RMP) for levetiracetam quantification in human serum and plasma. METHODS: Quantitative nuclear magnetic resonance spectroscopy (qNMR) was used to characterize the RMP material to ensure traceability to SI units. To quantify levetiracetam, an LC-MS/MS method was optimized using a C8 column for chromatographic separation following protein-precipitation-based sample preparation. Spiked matrix samples of serum and plasma were used to test selectivity and specificity. Matrix effects were determined by performing a post-column infusion experiment and comparing standard line slopes. Precision and accuracy were evaluated over 5 days. Measurement uncertainty was evaluated according to the Guide to the Expression of Uncertainty in Measurement (GUM). RESULTS: The RMP was proven to be highly selective and specific with no evidence of a matrix effect, allowing for quantification of levetiracetam within the range of 1.53-90.0 µg/mL. Intermediate precision was <2.2% and repeatability was 1.1-1.7% across all concentrations. The relative mean bias ranged from -2.5% to -0.3% across all levels and matrices within the measuring range. Diluted samples were found with a mean bias ranging from -0.1 to 2.9%. The predefined acceptance criterion for measurement uncertainty was met and determined for individual measurements independently of the concentration level and sample type to be ≤4.0% (k=2). CONCLUSIONS: We present a novel LC-MS/MS)-based candidate RMP for levetiracetam in human serum and plasma. Its expanded measurement uncertainty of ≤4.0% meets the clinical needs in levetiracetam monitoring. Utilizing qNMR to characterize levetiracetam reference materials allowed metrological traceability to SI units.
Asunto(s)
Isótopos , Espectrometría de Masas en Tándem , Humanos , Cromatografía Liquida/métodos , Espectrometría de Masas en Tándem/métodos , Levetiracetam , Reproducibilidad de los Resultados , Técnicas de Dilución del Indicador , Estándares de ReferenciaRESUMEN
OBJECTIVES: To develop an isotope dilution-liquid chromatography-tandem mass spectrometry-(ID-LC-MS/MS)-based candidate reference measurement procedure (RMP) for quantification of methotrexate in human serum and plasma. METHODS: Quantitative nuclear magnetic resonance (qNMR) was used to determine absolute methotrexate content in the standard. Separation was achieved on a biphenyl reversed-phase analytical column with mobile phases based on water and acetonitrile, both containing 0.1% formic acid. Sample preparation included protein precipitation in combination with high sample dilution, and method validation according to current guidelines. The following were assessed: selectivity (using analyte-spiked samples, and relevant structural-related compounds and interferences); specificity and matrix effects (via post-column infusion and comparison of human matrix vs. neat samples); precision and accuracy (in a five-day validation analysis). RMP results were compared between two independent laboratories. Measurement uncertainty was evaluated according to current guidelines. RESULTS: The RMP separated methotrexate from potentially interfering compounds and enabled measurement over a calibration range of 7.200-5,700 ng/mL (0.01584-12.54 µmol/L), with no evidence of matrix effects. All pre-defined acceptance criteria were met; intermediate precision was ≤4.3% and repeatability 1.5-2.1% for all analyte concentrations. Bias was -3.0 to 2.1% for samples within the measuring range and 0.8-4.5% for diluted samples, independent of the sample matrix. RMP results equivalence was demonstrated between two independent laboratories (Pearson correlation coefficient 0.997). Expanded measurement uncertainty of target value-assigned samples was ≤3.4%. CONCLUSIONS: This ID-LC-MS/MS-based approach provides a candidate RMP for methotrexate quantification. Traceability of methotrexate standard and the LC-MS/MS platform were assured by qNMR assessment and extensive method validation.
Asunto(s)
Metotrexato , Espectrometría de Masas en Tándem , Humanos , Cromatografía Liquida/métodos , Espectrometría de Masas en Tándem/métodos , Técnicas de Dilución del Indicador , Isótopos , Estándares de Referencia , Reproducibilidad de los ResultadosRESUMEN
In order to release correct biomarker results of a laboratory test, it is a regulatory requirement to apply quality control standards for controlling analytical errors. Releasing an incorrect test result might lead to wrong diagnosis or treatment of a patient in medical decision-making. In laboratory medicine, one of the means to control analytical errors is statistical process control procedures proposed by James O. Westgard and his coworkers nowadays known as "Westgard rules." To judge their performance for discriminating in-control from out-of-control processes, power curves are used. In this article, we describe functions for the power curves of the within-run Westgard rules. Based on these power curves, we use a benchmark approach for selecting a quality control procedure out of the set of Westgard rules. It is shown that two graphical procedures proposed by Westgard and his coworkers can be reduced to this benchmark approach. Besides, a commonly used measure in laboratory medicine for describing out-of-control processes is critically examined revealing the threat of selecting too optimistic quality control rules.
Asunto(s)
Técnicas de Laboratorio Clínico , Laboratorios , Biomarcadores , Humanos , Control de Calidad , Estándares de ReferenciaRESUMEN
INTRODUCTION: We define a designated data analytics workflow for the evaluation of stability experiments, which takes all data situations into account. This complements the evaluation described by the CLSI EP25 [1] guideline by including a targeted exception handling algorithm and thus allows one to automatically evaluate stability data based on linear regression analysis. DESCRIPTION: The evaluation of stability experiments based on regression analysis requires the calculation of the confidence interval of the regression line. The stability time is estimated at the intersection of the confidence interval with the acceptance criterion. This approach results in solving a quadratic equation, with factors that depend on the estimated intercept, slope, the measurement variability and the chosen timepoints. When defining an automated data analytics workflow for this problem, the different cases for the solutions of the quadratic equation must be considered. For some data situations there might be no solution at all, other data situations result in a negative and a positive solution and finally there might be even two positive solutions. All these cases have to be considered for the choice of the right solution to become the estimated stability time. The CLSI EP25 [1] guideline on stability evaluation of in vitro diagnostic reagents addresses this problem only superficially and might even lead to incorrect results for some specific data scenarios. RESULTS: We evaluate all possible data scenarios and provide examples for each. Based on the gained theoretical insights, we define a designated data analytics workflow and visualize it with a flowchart. By following this flowchart one can implement an automated analysis workflow, targeting all data scenarios with the appropriate exception handling. DISCUSSION: We deduce that the description for obtaining stability times according to CLSI EP25 is not fully adequate, as it addresses only best-case scenarios. However, for automated data analytics workflows all possible data situations have to be considered. With the here presented workflow one can program automated data analytics pipelines, which ensure that the right stability time is obtained, in case it exists. In addition all exceptions, where no stability times are present, are addressed in the right way and it provides hints as to the failure reason.
RESUMEN
The identification of outliers in method comparison studies (MCS) is an important part of data analysis, as outliers can indicate serious errors in the measurement process. Common outlier tests proposed in the literature usually require a homogeneous sample distribution and homoscedastic random error variances. However, datasets in MCS usually do not meet these assumptions. In this work, a new outlier test based on robust linear regression is proposed to overcome these special problems. The LORELIA (local reliability) residual test is based on a local, robust residual variance estimator, given as a weighted sum of the observed residuals. The new test is compared to a standard test proposed in the literature by a Monte Carlo simulation. Its performance is illustrated in examples.
Asunto(s)
Método de Montecarlo , Proyectos de Investigación/estadística & datos numéricos , Análisis de Varianza , Ensayos Clínicos como Asunto , Intervalos de Confianza , Estudios de Evaluación como Asunto , Humanos , Modelos LinealesRESUMEN
The accurate measurement of androstenedione in human serum and plasma is required for steroid profiling to assure the appropriate diagnosis and differential diagnosis of hyperandrogenism. In this work, we introduce an isotope dilution liquid chromatography-tandem mass spectrometry (LC-MS/MS) candidate reference measurement procedure for the quantification of androstenedione in human serum and plasma. The performance of the procedure enables its use in the evaluation and standardization of routine assays and for the evaluation of patient samples to ensure the traceability of individual patient results. As the primary standard, a certified reference material from NMIA (National Measurement Institute, Australia) was used. Additionally, a quantitative nuclear magnetic resonance (qNMR) method was developed for the value assignment of the primary reference material, which ensures the direct traceability to SI units, as well as the independence from the availability of reference materials. 13C3-labeled androstenedione was used as the internal standard. The introduced method allows the measurement of androstenedione in the range of 0.05-12 ng/mL, and the assay imprecision was found to be <2% between 5 and 12 ng/mL, 3.5% at 1.5 ng/mL, and 5.2% at 0.05 ng/mL, with an accuracy of 95-105% for the serum and 91-103% for the plasma matrix. The transferability to a second laboratory was validated by method comparison based on 112 patient samples. The comparison of the results obtained from the presented method and an LC-MS/MS routine assay, using 150 native patient samples, showed a good correlation with a bias of the routine method of ≤4.0%.
RESUMEN
BACKGROUND: The American Diabetes Association (ADA)/European Association for the Study of Diabetes (EASD)/International Diabetes Federation (IDF)/IFCC Consensus Statement on the worldwide standardization of HbA(1c) states that "... [HbA(1c)] results are to be reported world-wide in IFCC units ... and derived NGSP units ... , using the IFCC-NGSP master equation." METHODS: We describe statistical methods to evaluate and monitor the relationships as expressed in master equations (MEs) between the IFCC Reference Measurement procedure (IFCC-RM) and designated comparison methods (DCMs) [US National Glycohemoglobin Standardization Program (NGSP), Japanese Diabetes Society/Japanese Society for Clinical Chemistry (JDS/JSCC), and Mono-S in Sweden]. We applied these statistics, including uncertainty calculations, to 12 studies in which networks of reference laboratories participated, operating the IFCC-RM and DCMs. RESULTS: For NGSP and Mono-S, slope, intercept, and derived percentage HbA(1c) at the therapeutic target show compliance with the respective MEs in all 12 studies. For JDS/JSCC, a slight deviation is seen in slope and derived percentage HbA(1c) in 2 of the 12 studies. Using the MEs, the uncertainty in an assigned value increases from 0.42 mmol/mol HbA(1c) (IFCC-RM) to 0.47 (NGSP), 0.49 (JDS/JSCC), and 0.51 (Mono-S). CONCLUSIONS: We describe sound statistical methods for the investigation of relations between networks of reference laboratories. Application of these statistical methods to the relationship between the IFCC-RM and DCMs in the US, Japan, and Sweden shows that they are suitable for the purpose, and the results support the applicability of the ADA/EASD/IDF/IFCC Consensus Statement on HbA1c measurement.
Asunto(s)
Pruebas de Química Clínica/estadística & datos numéricos , Interpretación Estadística de Datos , Diabetes Mellitus/sangre , Hemoglobina Glucada/análisis , Pruebas de Química Clínica/métodos , Pruebas de Química Clínica/normas , Humanos , Japón , Programas Nacionales de Salud , Guías de Práctica Clínica como Asunto , Estándares de Referencia , Suecia , Incertidumbre , Estados UnidosRESUMEN
OBJECTIVE: To evaluate a new fully automated assay measuring antimüllerian hormone (AMH; Roche Elecsys) against antral follicle count in women of reproductive age. DESIGN: Prospective cohort study. SETTING: Hospital infertility clinics and academic centers. PATIENT(S): Four hundred fifty-one women aged 18 to 44 years, with regular menstrual cycles. INTERVENTION(S): None. MAIN OUTCOME MEASURE(S): AMH and antral follicle count (AFC) determined at a single visit on day 2-4 of the menstrual cycle. RESULT(S): There was a statistically significant variance in AFC but not in AMH between centers. Both AFC and AMH varied by age (overall Spearman rho -0.50 for AFC and -0.47 for AMH), but there was also significant between-center variation in the relationship between AFC and age but not for AMH. There was a strong positive correlation between AMH and AFC (overall spearman rho 0.68), which varied from 0.49 to 0.87 between centers. An agreement table using AFC cutoffs of 7 and 15 showed classification agreement in 63.2%, 56.9% and 74.5% of women for low, medium, and high groups, respectively. CONCLUSION(S): The novel fully automated Elecsys AMH assay shows good correlations with age and AFC in women of reproductive age, providing a reproducible measure of the growing follicle pool.
Asunto(s)
Hormona Antimülleriana/sangre , Análisis Químico de la Sangre/métodos , Infertilidad Femenina/diagnóstico , Folículo Ovárico/citología , Inducción de la Ovulación , Adolescente , Adulto , Automatización de Laboratorios , Análisis Químico de la Sangre/instrumentación , Recuento de Células , Femenino , Humanos , Infertilidad Femenina/sangre , Infertilidad Femenina/terapia , Folículo Ovárico/fisiología , Reserva Ovárica , Valor Predictivo de las Pruebas , Pronóstico , Adulto JovenRESUMEN
BACKGROUND: We performed a multicenter evaluation of the Elecsys® progastrin-releasing peptide (ProGRP) immunoassay in Europe and China. METHODS: The assay was evaluated at three European and two Chinese sites by imprecision, stability, method comparison and differentiation potential in lung cancer. RESULTS: Intermediate imprecision across five analyte concentrations ranged from 2.2% to 6.0% coefficient of variation. Good stability for plasma and serum samples was shown for various storage conditions. There was excellent correlation between the Elecsys® and ARCHITECT assays in plasma (slope 1.02, intercept -2.72pg/mL). The Elecsys® assay also showed good correlation between serum and plasma samples (slope 0.93, intercept 2.35pg/mL; correlation coefficient 0.97). ProGRP differentiated small-cell and non-small-cell lung cancer (NSCLC; area under the curve 0.90, 95% CI 0.87-0.93; 78.3% sensitivity, 95% specificity; at 84pg/mL), with no relevant effects of ethnicity, age, gender or smoking. Median ProGRP concentrations were low in benign diseases (38pg/mL), other malignancies (40pg/mL) or NSCLC (39pg/mL), except chronic kidney disease above stage 3 (>100pg/mL). CONCLUSIONS: Increased stability of the Elecsys® ProGRP assay in serum and plasma offers clear benefits over existing assays. This first evaluation of a ProGRP assay in China demonstrated comparable differentiation potential among different ethnicities.
Asunto(s)
Biomarcadores de Tumor/sangre , Carcinoma de Pulmón de Células no Pequeñas/diagnóstico , Carcinoma de Células Pequeñas/diagnóstico , Inmunoensayo/normas , Neoplasias Pulmonares/diagnóstico , Fragmentos de Péptidos/sangre , Adulto , Anciano , Área Bajo la Curva , Pueblo Asiatico , Carcinoma de Pulmón de Células no Pequeñas/sangre , Carcinoma de Pulmón de Células no Pequeñas/etnología , Carcinoma de Pulmón de Células no Pequeñas/patología , Carcinoma de Células Pequeñas/sangre , Carcinoma de Células Pequeñas/etnología , Carcinoma de Células Pequeñas/patología , China , Diagnóstico Diferencial , Europa (Continente) , Femenino , Humanos , Neoplasias Pulmonares/sangre , Neoplasias Pulmonares/etnología , Neoplasias Pulmonares/patología , Masculino , Persona de Mediana Edad , Proteínas Recombinantes/sangre , Sensibilidad y Especificidad , Población BlancaRESUMEN
A new graphical approach for analysis of measurement system comparison studies is proposed. Unlike the established linear regression and Bland-Altman analysis, it does not depend on the assumption of a linear relationship. We review the established analysis approaches and propose a difference plot with non-parametric regression as an adequate tool to describe the relationship between two measurement systems. Along with pre-defined level-dependent acceptance limits, this approach may provide evidence for metrological equivalence between two measurement systems. Several data examples are given to illustrate this approach.